Literature DB >> 975455

Angiotensin II and its heptapeptide (2-8), hexapeptide (3-8), and pentapeptide (4-8) metabolites in arterial and venous blood of man.

P F Semple, A S Boyd, P M Dawes, J J Morton.   

Abstract

We made separate measurements of angiotensin II (A II) and of its immunoreactive metabolites (2-8 heptapeptide, 3-8 hexapeptide, and 4-8 pentapeptide) in arterial and venous plasma from subjects with widely different plasma levels of the peptides. A II and its three metabolites were extracted from blood, separated by paper chromatography, and measured by radioimmunoassay using an A II antiserum which had a 100% cross-reaction with each metabolite. In contrast to results of previous studies, A II was found to predominate in both arterial (60-100%) and venous (55-100%) blood. The biologically active 2-8 heptapeptide metabolite accounted for only 10% of the activity in arterial plasma. Radioimmunoassay of venous plasma extracts using an A II antiserum which had a low cross-reaction with the 3-8 hexapeptide and the 4-8 pentapeptide confirmed the results obtained using the antiserum which had a 100% cross-reaction with the metabolites. We conclude that radioimmunoassay methods for measuring A II in venous blood may be more accurate and relevant than has previously been recognized. The small difference between A II concentrations in arterial and venous plasma suggests further that there may be significant conversion of angiotensin I (A I) to A II in the limb vasculature.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 975455     DOI: 10.1161/01.res.39.5.671

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  14 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 2.  Circulating and tissue angiotensin systems.

Authors:  D J Campbell
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

Review 3.  Biochemistry and pharmacology of the renin-angiotensin system.

Authors:  C I Johnston
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 4.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good.

Authors:  Ping Xu; Srinivas Sriramula; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-22       Impact factor: 3.619

Review 5.  [The renin-angiotensin system in diabetic patients].

Authors:  J Mann; E Ritz
Journal:  Klin Wochenschr       Date:  1988-09-15

6.  Ultrastructural immunocytochemical localization of renin and angiotensin II in the juxtaglomerular cells of the ischemic kidney in experimental renal hypertension.

Authors:  M Cantin; J Gutkowska; J Lacasse; M Ballak; S Ledoux; T Inagami; J Beuzeron; J Genest
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

7.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

8.  Total immunoreactive angiotensin ii, its hepta-octapeptide fraction, and its hexapeptide in patients with liver disease.

Authors:  H J Spech
Journal:  Klin Wochenschr       Date:  1978-04-15

9.  Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.

Authors:  R M Carey; E D Vaughan; M J Peach; C R Ayers
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

10.  Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.

Authors:  Amy C Arnold; Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-12-24       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.